Case report: Clearance of longstanding, immune-deficiency-associated, vaccine-derived polio virus infection following remdesivir therapy for chronic SARS-CoV-2 infection
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
The global polio eradication campaign has had remarkable success in reducing wild-type poliovirus infection, largely built upon the live attenuated Sabin oral poliovirus vaccine. Whilst rare, vaccine poliovirus strains may cause infection and subsequently revert to a neurovirulent type, termed vaccine-derived poliovirus (VDPV). Persistent, vaccine derived infection may occur in an immunocompromised host (iVDPV), where it is a recognised complication following receipt of the Sabin vaccine. This has significant implications for the global polio eradication campaign and there is currently no agreed global strategy to manage such patients.Here we describe a case of a 50-year-old man with common variable immune deficiency, persistently infected with a neurovirulent vaccine-derived type 2 poliovirus following vaccination in childhood. iVDPV infection had proven resistant to multiple prior attempts at treatment with human breast milk, ribavirin and oral administration of a normal human pooled immunoglobulin product. His iVDPV infection subsequently resolved after 12 days treatment with remdesivir, an adenosine analogue prodrug that is an inhibitor of viral RNA-dependent RNA polymerase, administered as treatment for a prolonged, moderate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. iVDPV from the patient, isolated prior to treatment, was subsequently demonstrated to be sensitive to remdesivir in vitro. Based on the observations made in this case, and the mechanistic rationale for use with iVDPV, there is strong justification for further clinical studies of remdesivir treatment as a potentially curative intervention in patients with iVDPV infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A recent study reported that remdesivir treatment eliminated iVDPV in the stool of a 50-year-old patient.”
From The Fight against Poliovirus Is Not Over (2023) · cites this paper as [139]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These results suggest that remdesivir may be effective in the treatment of iVDPV [139].”
From The Fight against Poliovirus Is Not Over (2023) · cites this paper as [139]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Burns, C. C., Diop, O. M., Sutter, R. W., & Kew, O. M. (2014) · Journal of Infectious Diseases · doi:10.1093/infdis/jiu295 · Cited by 309 · cited 2×
“With wild-type infections now suppressed throughout much of the world, vaccinederived poliovirus (VDPV) infections present a significant challenge to the WHO global polio eradication initiative (2).”
BackgroundThe National Early Warning Score 2 (NEWS2)
Smith, G. B., Redfern, O. C., Pimentel, M. A., Gerry, S., Collins, G. S., Malycha, J., Prytherch, D., Schmidt, P. E., & Watkinson, P. J. (2019) · Clinical Medicine · doi:10.7861/clinmedicine.19-3-260 · Cited by 177 · cited 1×
“On admission, he was febrile with a NEWS2 score (7) of 2 (pyrexia/tachycardia); C-reactive protein (CRP) was raised at 59 mg/L (0–5 mg/L).”
BackgroundMacLennan, C., Dunn, G., Huissoon, A. P., Kumararatne, D. S., Martin, J., O'Leary, P., Thompson, R. A., Osman, H., Wood, P., Minor, P., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16150-3 · Cited by 162 · cited 1×
“Further details of these treatments are available in a previously published work (6).”
BackgroundSelf-citationKlapsa, D., Wilton, T., Zealand, A. M., Bujáki, E., Saxentoff, E. V., Troman, C. M., Shaw, A., Tedcastle, A. B., Majumdar, M., Mate, R., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01804-9 · Cited by 150 · cited 1×
“A recent detection of VDPV type 2 poliovirus in London sewage demonstrates that this is a demonstrable risk to populations (11).”
BackgroundSelf-citationDunn, G., Klapsa, D., Wilton, T., Stone, L., Minor, P. D., & Martin, J. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1005114 · Cited by 106
Self-citationTreatment of chronic or relapsing COVID-19 in immunodeficiency
Brown, L. K., Moran, E., Goodman, A. L., Baxendale, H., Bermingham, W. H., Buckland, M. S., Abdul-Khaliq, I., Jarvis, H., Hunter, M., Karanam, S., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.10.031 · Cited by 94 · cited 1×
“SARS-CoV-2specific neutralising monoclonal antibodies were not available for this patient’s treatment (8).”
BackgroundSelf-citationMacklin, G., Diop, O. M., Humayun, A., Shahmahmoodi, S., El-Sayed, Z. A., Triki, H., Rey, G., Avagyan, T., Grabovac, V., Jorba, J., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6928a4 · Cited by 46 · cited 3×
“Patients with iVDPV are predominantly reported in those with severe combined immune deficiency or hypogammaglobulinaemia (3).”
BackgroundRemdesivir (GS-5734) Impedes Enterovirus Replication Through Viral RNA Synthesis Inhibition
Ye, W., Yao, M., Dong, Y., Ye, C., Wang, D., Liu, H., Ma, H., Zhang, H., Qi, L., Yang, Y., et al. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.01105 · Cited by 42 · cited 1×
“Whilst it has not been explicitly demonstrated to inhibit poliovirus, the conserved nature of viral RdRps suggests that it likely has activity against the poliovirus RdRp, too (13).”
BackgroundKankam, M. K., Burns, J. M., Collett, M. S., Corrado, M. L., & Hincks, J. R. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01029-21 · Cited by 17
Poliovirus Vaccination Induces a Humoral Immune Response That Cross Reacts With SARS-CoV-2
Comunale, B. A., Engineer, L. D., Jiang, Y., Andrews, J. C., Liu, Q., Ji, L., Yurkovich, J. T., Comunale, R. A., & Xie, Q. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.710010 · Cited by 16
Research works printed but not linked: 2
- 2021, Polio eradication strategy 2022–2026: Delivering on a promise
- 2013, The approved list of biological agents, Heal Saf Exec, 1
Cited by
The Fight against Poliovirus Is Not Over
Mbani, C. J., Nekoua, M. P., Moukassa, D., & Hober, D. (2023) · Microorganisms · doi:10.3390/microorganisms11051323 · Cited by 34
The multiple roles of viral 3D pol protein in picornavirus infections
Nie, Z., Zhai, F., Zhang, H., Zheng, H., & Pei, J. (2024) · Virulence · doi:10.1080/21505594.2024.2333562 · Cited by 14
“Similarly, current clinical data showed that vaccine-derived polio-virus infection in an immunocompromised patient was cured by GS-5734 treatment after multiple failed attempts to treat with human milk, ribavirin, and oral human immunoglobulin [101].”
BackgroundEstívariz, C. F., Krow‐Lucal, E., & Mach, O. (2024) · Pathogens · doi:10.3390/pathogens13121128 · Cited by 10
Badizadegan, K., & Thompson, K. M. (2025) · PLOS Global Public Health · doi:10.1371/journal.pgph.0004168 · Cited by 5
“…global cessation of type 2 OPV in 2016, containment requirements for type 2 led clinical laboratories to end serological testing for type 2, which limited (censored) the information available related to ongoing excretion by a chronic iVDPV excreter after 2018 as highlighted by others [115].”
Health Economic Analysis of Antiviral Drugs in the Global Polio Eradication Endgame
Badizadegan, K., Kalkowska, D. A., & Thompson, K. M. (2023) · Medical Decision Making · doi:10.1177/0272989x231191127 · Cited by 5
“63 Generally, the regulatory path to approval of a specific PAVD continues to prove more challenging than might occur with the potential off-label use or repurposing of an existing antiviral or anti-enteroviral drug.”
Background
Metadata
- Authors
- Bermingham, W. H., Canning, B., Wilton, T., Kidd, M., Klapsa, D., Majumdar, M., Sooriyakumar, K., Martin, J., & Huissoon, A. P.
- Affiliations
- University Hospitals Birmingham NHS Foundation Trust (GB)
- Nottingham University Hospitals NHS Trust (GB)
- Medicines and Healthcare products Regulatory Agency (GB)
- UK Health Security Agency (GB)
- Corresponding author
- Bermingham, William Hywel
- ORCID
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2023-03-03
- Volume
- 14
- Pages
- 1135834-1135834
- ISSN
- 1664-3224 (ISSN-L)
- PMC
- PMC10022663
- OpenAlex
- W4323045444
- Cited by
- 15
- References
- 12
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 2 · 2023: 2
- FWCI
- 2.95
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Immunology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- University Hospitals Birmingham NHS Foundation Trust
- Topics
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Health Sciences › Medicine › Infectious Diseases › Viral gastroenteritis research and epidemiology
- Keywords
- vaccine-derived poliovirus, remdesivir, common variable immunodeficiency, viral persistence, COVID-19 pandemic, antiviral therapy, RNA-dependent RNA polymerase inhibition, polio eradication, ribavirin
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Drug Treatment, Adenosine Monophosphate, Alanine, Female, Humans, Immunologic Deficiency Syndromes, Male, Middle Aged, Poliomyelitis, Poliovirus Vaccine, Oral, Poliovirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Case report: Clearance of longstanding, immune-deficiency-associated, vaccine-derived polio virus infection following remdesivir therapy for chronic SARS-CoV-2 infection. https://app.cochat.ai/papers/10.3389/fimmu.2023.1135834
- The paper
- Bermingham, W. H., Canning, B., Wilton, T., Kidd, M., Klapsa, D., Majumdar, M., Sooriyakumar, K., Martin, J., & Huissoon, A. P. (2023). Case report: Clearance of longstanding, immune-deficiency-associated, vaccine-derived polio virus infection following remdesivir therapy for chronic SARS-CoV-2 infection. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2023.1135834
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.